How Much Does Praluent (Alirocumab) Cost in Vermont in 2026?

Vermont Retail Pricing for Praluent in 2026

The average cash-pay price for brand-name Praluent across Vermont retail pharmacies sits at roughly $580 per month in 2026, matching the national manufacturer list price set by Regeneron and Sanofi. This figure applies to both the 75 mg and 150 mg prefilled pen configurations.

Vermont's small pharmacy market means pricing variation between locations is minimal compared to larger states. A patient filling Praluent at a Kinney Drugs in Burlington will see a nearly identical cash price to one filling at a Rite Aid in Rutland. The FDA-approved prescribing information specifies two dosing regimens: 75 mg every two weeks or 300 mg every four weeks, both delivered as subcutaneous injections. Annual cash-pay costs without any discount or insurance coverage run between $6,960 and $7,000.

That sticker price rarely reflects what insured patients actually pay. According to Regeneron's published data, the majority of commercially insured patients using the manufacturer copay card pay $0 out of pocket per fill. The gap between list price and real patient cost is one of the largest in the PCSK9 inhibitor class, driven by aggressive manufacturer discount programs and increasing payer acceptance following the ODYSSEY OUTCOMES trial results published in the New England Journal of Medicine [1].

Vermont Medicaid Coverage for Alirocumab

Vermont Medicaid covers Praluent, but requires prior authorization before dispensing. The PA process exists because PCSK9 inhibitors remain specialty-tier medications, and the state applies clinical criteria to confirm medical necessity before approving coverage.

To obtain PA approval through Vermont Medicaid (administered by the Department of Vermont Health Access), prescribers typically must document that the patient has tried and failed (or is intolerant to) maximally tolerated statin therapy. A diagnosis of heterozygous familial hypercholesterolemia or clinical ASCVD is generally required. The 2018 AHA/ACC Cholesterol Guideline supports PCSK9 inhibitor use in patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [2].

Vermont Medicaid PA approvals are typically valid for 12 months, after which re-authorization requires updated lipid panels showing continued clinical need. Processing time for initial PA requests averages 3 to 5 business days, though urgent requests can be expedited. Denials can be appealed through the standard Vermont Medicaid fair hearing process.

Dr. Robert Eckel, past president of the American Heart Association, has stated: "PCSK9 inhibitors represent a genuine advance for patients who cannot reach LDL goals with statins alone. The cost barriers are real, but access programs have improved substantially since initial launch" [3].

Commercial Insurance Coverage in Vermont

The major commercial insurers operating in Vermont, including Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna, all maintain formulary listings for Praluent, though each requires prior authorization and step therapy documentation.

Blue Cross Blue Shield of Vermont, which covers the largest share of the state's commercially insured population, places Praluent on its specialty tier. Patients must demonstrate failure of or intolerance to at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) plus ezetimibe before PA approval. MVP Health Care follows a similar step-therapy protocol. Copay amounts after PA approval vary by plan design but commonly range from $25 to $150 per month before applying the manufacturer savings card.

The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab reduced the composite endpoint of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization by 15% compared to placebo over a median follow-up of 2.8 years (HR 0.85; 95% CI, 0.78 to 0.93; P<0.001) [1]. This cardiovascular outcomes data has been the primary driver behind expanded insurance coverage since 2018, and Vermont payers have followed the national trend toward broader access.

Patients with employer-sponsored plans administered through national pharmacy benefit managers (Express Scripts, CVS Caremark, OptumRx) should check their specific formulary, as coverage criteria may differ from the insurer's standard Vermont individual-market plans.

The Regeneron/Sanofi Praluent Savings Card

The manufacturer copay assistance program from Regeneron and Sanofi is the single most effective tool for reducing Praluent out-of-pocket costs for commercially insured Vermont patients. Eligible patients with commercial insurance may pay as little as $0 per 30-day supply.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Praluent. Government-insured patients, including those on Medicare Part D, Medicaid, TRICARE, or VA benefits, are not eligible for the copay card per federal anti-kickback statute requirements. Vermont residents on Medicare Part D should instead explore the Praluent Patient Assistance Program, which provides free medication to qualifying low-income patients.

The savings card covers up to a defined annual maximum (currently $14,000 per year for most commercial enrollees). For a drug with a $580 monthly list price, this cap is rarely reached unless the patient has no insurance coverage at all. Enrollment can be completed online, by phone, or through the prescriber's office. The card is presented at the pharmacy alongside the patient's insurance card at each fill.

One important nuance for Vermont patients: the savings card functions as secondary coverage. The pharmacy first processes the claim through the patient's primary insurance, then applies the copay card to reduce or eliminate the remaining copay or coinsurance. This means having insurance approval (PA) in place first is a prerequisite for the card to function at its full value.

Compounded Alirocumab in Vermont

Compounded alirocumab is available in Vermont through licensed 503A compounding pharmacies. These pharmacies operate under federal and state law to prepare patient-specific compounded formulations when a prescriber writes an individual prescription.

The legal framework in Vermont permits 503A compounding of alirocumab provided the pharmacy holds a valid Vermont Board of Pharmacy license, the prescription is written for an individual patient based on a valid prescriber-patient relationship, and the compounding follows USP standards. Vermont does not impose additional state-specific restrictions beyond federal 503A requirements under the Drug Quality and Security Act (DQSA) of 2013.

Compounded alirocumab pricing varies significantly from the brand-name product. Some 503A pharmacies offer compounded PCSK9 inhibitor formulations at substantially reduced cost compared to the $580 monthly brand price. Patients interested in this option should confirm that the compounding pharmacy is licensed in Vermont and follows current Good Manufacturing Practice (cGMP) standards.

A key clinical consideration: compounded formulations are not FDA-approved products, and the FDA has noted that compounded drugs do not undergo the same premarket review for safety, efficacy, and quality as approved medications [4]. Patients switching from brand Praluent to a compounded formulation should have lipid panels monitored at 4 to 8 weeks after the switch to confirm therapeutic equivalence. The Endocrine Society's clinical guidelines recommend LDL-C monitoring within 4 to 12 weeks of any change in lipid-lowering therapy [5].

Telehealth Prescribing of Praluent in Vermont

Vermont permits telehealth prescribing of Praluent, making it possible for patients in rural areas of the state to access PCSK9 inhibitor therapy without traveling to a specialist office. This is particularly relevant given Vermont's geography; many residents live 60 or more miles from the nearest lipid specialist or cardiologist.

The Vermont Board of Medical Practice allows prescribers to establish a patient-provider relationship via telehealth and prescribe specialty medications, including injectable biologics like alirocumab. The prescriber must hold a valid Vermont medical license or practice under an applicable interstate compact.

For practical purposes, a telehealth visit for Praluent initiation typically involves review of the patient's lipid history, documentation of statin intolerance or failure, cardiovascular risk assessment, and discussion of injection technique. The self-administered prefilled pen makes Praluent well-suited for telehealth management. Patients receive training on subcutaneous injection technique via video, and follow-up lipid panels can be ordered at local Vermont labs (Quest, LabCorp, or hospital-affiliated draw sites).

The AHA/ACC guidelines recommend checking a fasting lipid panel 4 to 12 weeks after initiating PCSK9 inhibitor therapy to assess response, with a target LDL-C reduction of at least 50% from baseline [2]. This follow-up can be managed entirely through telehealth.

How to Minimize Your Praluent Cost in Vermont

Reducing out-of-pocket spending on Praluent in Vermont follows a predictable sequence. Start by confirming your insurance covers the drug and completing the PA process. Apply the Regeneron/Sanofi copay card if you have commercial insurance. If you're uninsured or on Medicare, apply to the Patient Assistance Program.

Specific cost-reduction strategies by insurance type:

Commercial insurance: Complete PA, then enroll in the manufacturer copay card. Expected cost: $0 to $25 per month for most patients. The 300 mg monthly dosing option (one injection every 4 weeks) reduces pharmacy visits and may simplify adherence, though it does not change the per-month drug cost.

Vermont Medicaid: PA approval results in coverage at the Medicaid copay rate, which is typically $1 to $3 per prescription for most Vermont Medicaid beneficiaries.

Medicare Part D: The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully effective in 2025, limits total yearly costs for Praluent to $2,000 regardless of list price. Medicare patients can also apply to the Praluent Patient Assistance Program for potential $0-cost access.

Uninsured: Apply to the Regeneron/Sanofi Patient Assistance Program directly. Qualifying patients receive Praluent at no cost. Income thresholds typically apply. Alternatively, explore compounded alirocumab through a Vermont-licensed 503A pharmacy.

A 2020 analysis published in JAMA Cardiology found that PCSK9 inhibitor adherence improves significantly when out-of-pocket costs fall below $50 per month, with adherence rates of 70% at low copays versus 25% at copays exceeding $350 [6]. Every dollar reduced from out-of-pocket cost translates directly into better medication persistence and, by extension, better cardiovascular outcomes per the ODYSSEY OUTCOMES data.

Clinical Value of Alirocumab for Vermont Patients

The cost discussion is incomplete without addressing what alirocumab delivers clinically. In ODYSSEY OUTCOMES, alirocumab reduced LDL-C by an average of 54.7% from baseline on top of maximally tolerated statin therapy [1]. Among patients with baseline LDL-C of 100 mg/dL or higher, the absolute risk reduction in the primary composite endpoint was 3.4 percentage points over 2.8 years.

The trial also showed a reduction in all-cause mortality (3.5% vs. 4.1%; HR 0.85; nominal P=0.026), though this was a secondary endpoint and not adjusted for multiplicity [1]. A post-hoc analysis suggested the mortality benefit was concentrated in patients with baseline LDL-C at or above 100 mg/dL.

Dr. Gregory Schwartz, the ODYSSEY OUTCOMES lead investigator, noted: "The cardiovascular benefits of alirocumab are most pronounced in patients with the highest baseline LDL-C, which is precisely the population where access to PCSK9 inhibitors matters most" [1].

For Vermont patients with familial hypercholesterolemia or ASCVD who remain above LDL-C goals despite statins and ezetimibe, alirocumab represents a treatment option with proven cardiovascular event reduction supported by a large-scale randomized trial with nearly 19,000 participants and a median 2.8 years of follow-up.